Genie Biotech has developed a patent-pending, site-specific 'GenieTagTM' conjugation technology with the unique feature being slow and conditional reversibility of the tag. The application of the technology has been pre-clinically demonstrated for the protein-based, multimerized SARS-CoV-2 vaccine candidate. At the moment, the company is focusing on applying 'GenieTagTM' technology for prophylactic as well as therapeutic cancer vaccines, conditionally-active/'masked' protein therapeutics, and novel slow-release technologies for biologics. We are looking for partnering, licensing, and acquisition opportunities as well as providing R&D services.
Company code: 305529882
Genie Biotech EU, UABContact the company (B2B)
Biotech, biochemical, and pharmaceutical industry
Current export markets:
Export turnover: 0%